Intimate Wellness · Hormones

The Appointment Nobody Books: Low Libido, Explained

By Dr. G — Carrie Giordano, DO, FACOG, DABOM, MSCP · Wahine Health, Wailea, Maui · August 2026

You love your partner. The desire just isn’t showing up. Or it is — but sex hurts now, so you’ve started finding reasons to be asleep first. Or your body simply doesn’t respond the way it used to, and you’ve quietly concluded that this part of your life is winding down.

Here’s what I want you to know before you read another word: none of those is a personality change, a character flaw, or an inevitability. Each one is a symptom — and symptoms have workups.

Low sexual desire is one of the most common concerns of the menopause transition and one of the least discussed in exam rooms. Roughly a third of midlife women report low desire, and for about one in ten it’s distressing enough to meet criteria for hypoactive sexual desire disorder — HSDD, the actual clinical diagnosis. Yet it almost never comes up at the annual visit, because “my sex drive disappeared” feels like a confession rather than a chief complaint.

It’s a chief complaint. Let’s treat it like one.

Three systems, three levers

The single most useful reframe I can offer is this: what we casually call “libido” is actually three different systems, and they fail — and respond to treatment — separately.

• Desire lives in the brain. It runs on neurochemistry — dopamine, oxytocin, serotonin — and on the hormones that modulate them, including estrogen and testosterone.
• Comfort lives in the tissue. Vaginal and vulvar tissue is dense with estrogen receptors, and when estrogen falls, tissue thins, dries, and loses elasticity. If sex hurts, desire follows comfort down — that’s not psychology, it’s learning.
• Arousal and response live in blood flow, nerves, and muscle — pelvic blood flow, tissue sensitivity, and the pelvic floor musculature that literally generates orgasm intensity.

A workup that only looks at one system misses the other two. A woman treated for “low libido” with testosterone alone, while her tissue pain goes unaddressed, doesn’t get better. Neither does the woman handed a lubricant when the actual problem is upstream, in the brain chemistry of wanting. The sorting matters.

Desire lives in the brain

Two brain chemicals do most of the work here, and understanding them is genuinely useful.

Dopamine is the chemistry of wanting. It drives anticipation, motivation, reward — the pull toward something before it happens. Estrogen supports dopamine signaling, which is one reason desire can flatten across perimenopause even when nothing else is “wrong.” It’s also why SSRIs, which raise serotonin and functionally dampen dopamine tone, so commonly blunt libido — and why the two FDA-approved medications for HSDD both work on this axis. Flibanserin adjusts the serotonin–dopamine balance; bremelanotide activates melanocortin receptors upstream of dopamine pathways. I mention them not as a sales pitch but as proof of principle: the FDA has approved two drugs for low desire in women because low desire is a neurochemical condition, not a mindset problem.

Oxytocin is the chemistry of bonding. It’s released with touch, closeness, and orgasm, and it lowers the threshold for the next encounter. This is why intimacy compounds in both directions: connection begets desire, and avoidance begets avoidance. When sex has become disappointing or painful, the oxytocin loop runs in reverse — each skipped encounter makes the next one feel further away. Recognizing that loop as physiology, not failure, is often the thing that lets couples stop taking it personally.

Desire has an accelerator and brakes — and midlife mostly adds brakes. Fatigue, night sweats, pain, an unforgiving mirror. The accelerator usually still works. The job is finding the brakes.

One more piece of brain science worth having: responsive desire is normal. Many women — especially in long relationships and especially in midlife — don’t experience desire spontaneously out of nowhere. Desire shows up after arousal begins, in response to it. If you’ve been waiting to feel like it before starting, and concluding something is broken because the feeling never arrives unprompted — nothing is broken. Your desire style may simply be responsive, which changes the strategy entirely.

The testosterone conversation

Testosterone is not a male hormone that women have a little of. Women produce it throughout life — before menopause, your ovaries and adrenals make more testosterone than estrogen, by quantity — and levels decline gradually through the 30s and 40s.

Here is the honest state of the evidence. Testosterone’s best-established indication is HSDD — distressing low desire — where a global consensus statement and multiple trials support its use in postmenopausal women. For everything else you’ve seen claimed on social media — muscle, bone, cognition — the research is active and genuinely interesting, but not yet conclusive, and I won’t pretend otherwise.

There’s no FDA-approved female testosterone product in the United States, so treatment involves either off-label microdosing of a male product or compounding — and which route makes sense for you is an individualized decision we make together in a visit.

When sex hurts: this is the most fixable thing on the page

Genitourinary syndrome of menopause — GSM — is the clinical name for what falling estrogen does to vaginal and vulvar tissue: thinning, dryness, burning, tearing, pain with sex, and the urinary symptoms that often travel with it. It affects over half of postmenopausal women, it does not get better on its own, and it is profoundly treatable.

First-line treatment is local vaginal estrogen — cream, tablet, or ring. The dose is tiny and acts locally on the tissue that needs it. Two things patients are consistently relieved to learn: local vaginal estrogen does not require a progestogen alongside it, and it can be appropriate even for many women who can’t or don’t want to take systemic hormone therapy. Tissue that has thinned over years typically begins to recover within weeks.

And there’s a second FDA-approved option many women have never heard of: vaginal DHEA (prasterone), a nightly insert that converts locally into both estrogens and androgens within the vaginal tissue itself. It’s a different mechanism than vaginal estrogen — and for some women, a better fit. Which one suits you is exactly the kind of decision a visit is for.

If sex hurts, that alone is worth an appointment — this is among the most satisfying things we treat. Read more about intimate wellness care, or book a visit.

Beyond hormones: the options most women don’t know exist

When tissue quality, blood flow, or muscle need more support than hormones alone provide, we have in-office tools most women have never been told about.

• FemiLift is a fractional CO₂ laser that stimulates collagen remodeling in vaginal tissue — improving thickness, elasticity, and lubrication over a short series of comfortable office treatments. We position it honestly: FemiLift is an adjunct to local vaginal estrogen, not a replacement for it. The combination is where we see the best results.
• EmFemme 360 uses radiofrequency energy to gently heat vaginal tissue, supporting blood flow and tissue tone. Sessions are quick and comfortable — many patients describe it as a warm massage.
• truFlex pelvic floor strengthening uses electrical muscle stimulation to train the pelvic floor — the muscle group that generates orgasm intensity and supports continence. A stronger pelvic floor is one of the most underrated levers in sexual response, and this one requires no effort beyond showing up.
• Topical arousal cream — yes, it’s really called “scream cream.” A compounded cream applied locally before intimacy, typically built around vasodilating ingredients that increase blood flow and sensitivity right where it counts. It works on the arousal system directly — and for women whose desire is intact but whose response has dimmed, it can be a genuinely useful tool.
• Oxytocin troches. The bonding hormone itself, compounded into a lozenge. We’ll be honest with you the way we always are: the trial evidence here is early and mixed, which is why this is a case-by-case conversation rather than a blanket recommendation — but for the right patient it has a place in the plan.
• Peptide therapy for sexual vitality. Bremelanotide — the melanocortin agonist mentioned above — exists as an FDA-approved product, and related peptides are available through compounding pharmacies. The most interesting emerging name is kisspeptin, a neuropeptide upstream of the entire reproductive hormone axis: early trials in women with HSDD showed enhanced sexual brain processing. It’s investigational — which is exactly the kind of thing worth discussing in a visit rather than buying off the internet.

What about supplements?

The libido-supplement aisle is enormous and mostly marketing, so let me be specific. Maca has modest randomized-trial evidence for sexual function, including some data in antidepressant-associated sexual dysfunction — the effect sizes are small but real. Beyond that, most “female libido blends” are underdosed botanicals with better copywriting than data. The supplements that help most women’s sex lives are often the unsexy ones — correcting the iron, vitamin D, or sleep-supporting deficits that testing actually finds — because exhaustion is the most common anti-aphrodisiac in midlife.

And the part that isn’t a prescription

I’d be doing you a disservice if I ended without saying this: hormones, lasers, and peptides work on the body, and the body is only part of the story. Relationship strain, chronic stress, body image, past experiences, a partner’s health — these sit on the brakes too, and no cream reaches them. Sometimes the most effective part of a treatment plan is a referral to a good sex therapist or couples counselor, alongside the medical work. Naming that isn’t a consolation prize. It’s a complete workup.

This is a workup, not a resignation

Here’s what an actual visit looks like: a real history — desire, comfort, arousal, relationship, medications, sleep. An exam when indicated. Labs when indicated. And then a plan built from the full toolkit — hormonal, tissue-based, device-based, and human — matched to which system is actually struggling.

Most women leave that visit with two things they haven’t had in a while: a plan, and the experience of having said the thing out loud to someone who didn’t flinch.

This article is patient education and is not a substitute for individualized medical advice. Treatment candidacy for hormone therapy, laser treatment, and peptide therapy is determined in a visit. Individual results vary.